Aptuit, a global drug discovery and development CRO, and Icagen, which provides scientific expertise and comprehensive access to technologies for ion channel and transporter assays, announced a strategic alliance aimed to provide comprehensive and integrated services and access to best-in-class fully integrated drug discovery and development solutions for the specific target classes, supported by a shared culture of scientific excellence and innovation.

The strategic alliance will give Aptuit’s customers access to Icagen’s portfolio of assay tools, including the extensive collection of unique ion channel cell lines and their proprietary XRpro® X-ray fluorescence technology platform. Icagen’s customers are expected to benefit from Aptuit’s wide range of integrated drug discovery solutions, including medicinal chemistry, in vitro DMPK, discovery pharmacology, computational chemistry and best-in-class analytical discovery support.